The value of serum Cyfra21-1 as a biomarker in the diagnosis of patients with non-small cell lung cancer: A meta-analysis

Journal of Cancer Research and Therapeutics

Volumn 10, Issue , 2014, Pages C131-C134

  Cui, Chao ^a   Sun, Xin ^a   Zhang, Jun ^a   Han, Dong ^a   Gu, Jundong ^b  

^a Tianjin Haihe Hospital   (China)

^b TIANJIN UNION MEDICAL CENTER   (China)

Author keywords

Cyfra21 1; diagnosis; meta analysis; nonsmall cell lung carcinoma

Indexed keywords

BIOLOGICAL MARKER; CYTOKERATIN 19 FRAGMENT; ANTIGEN CYFRA21.1; CYTOKERATIN 19; TUMOR ANTIGEN; TUMOR MARKER;

ARTICLE; CANCER DIAGNOSIS; CANCER PATIENT; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; HUMAN; META ANALYSIS; NON SMALL CELL LUNG CANCER; PROTEIN BLOOD LEVEL; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW; BLOOD; CARCINOMA, NON-SMALL-CELL LUNG; COMPUTER PROGRAM; LABORATORY DIAGNOSIS; LUNG NEOPLASMS; RECEIVER OPERATING CHARACTERISTIC;

ANTIGENS, NEOPLASM; CARCINOMA, NON-SMALL-CELL LUNG; FALSE NEGATIVE REACTIONS; FALSE POSITIVE REACTIONS; HUMANS; KERATIN-19; LUNG NEOPLASMS; ROC CURVE; SENSITIVITY AND SPECIFICITY; SOFTWARE; TUMOR MARKERS, BIOLOGICAL;

EID: 84916597760     PISSN: 09731482     EISSN: 19984138     Source Type: Journal    
DOI: 10.4103/0973-1482.145835     Document Type: Article

References (22)

1. Kulpa J, Wójcik E, Reinfuss M, Kolodziejski L. Carcinoembryonic antigen, squamous cell carcinoma antigen, CYFRA 21-1, and neuron-specific enolase in squamous cell lung cancer patients. Clin Chem 2002;48:1931-7.
2. Rastel D, Ramaioli A, Cornillie F, Thirion B. CYFRA 21-1, a sensitive and specific new tumour marker for squamous cell lung cancer. Report of the first European multicentre evaluation. CYFRA 21-1 multicentre study group. Eur J Cancer 1994;30A:601-6.
3. Huang MS, Jong SB, Tsai MS, Lin MS, Chong IW, Lin HC, et al. Comparison of cytokeratin fragment 19 (CYFRA 21-1), tissue polypeptide antigen (TPA) and carcinoembryonic antigen (CEA) as tumour markers in bronchogenic carcinoma. Respir Med 1997;91:135-42.
4. Niklinski J, Furman M, Chyczewska E, Chyczewski L, Rogowski F, Laudanski J. Diagnostic and prognostic value of the new tumour marker CYFRA 21-1 in patients with squamous cell lung cancer. Eur Respir J 1995;8:291-4.
5. Ebert W, Dienemann H, Fateh-Moghadam A, Scheulen M, Konietzko N, Schleich T, et al. Cytokeratin 19 fragment CYFRA 21-1 compared with carcinoembryonic antigen, squamous cell carcinoma antigen and neuron-specific enolase in lung cancer. Results of an international multicentre study. Eur J Clin Chem Clin Biochem 1994;32:189-99.
6. Xu PS. CYFRA 21-1 in the diagnosis of lung cancer. Tumor 1996 ;6:123-4.
7. Xiong Y, Fang ZY, Song XY. The clincial value of several tumor marker in the diagnosis of lung cancer. Chin J Coal Ind Med 2001 ;11:721-2.
8. Pan QR, Zhao X, Cao J, Cao YL. Study on the correlationship between CK19 mRNA and CyFRA21-1 in peripheral blood of lung cancer patients. Chin J Lab Diagn 2002;6:374-6.
9. Xia Y, Zhao BQ, Ying KJ. Serum CYFRA21-1 and CEA in the diagnosis of non-small cell lung cancer. Zhejiang Med J 2003;25:189-90.
10. Huang WC, Cao C, Pan H, Zeng B, Huang LS, Cui L, et al. Combined array of serum TSGF, NSE and CYFRA21-1 for diagnosis of luung cancer. China J Mod Med 2008 ;8:305-8, 312.
11. Duan HJ, Huang XZ. Clinical significance of tumor marker CYFRA21-1 in patients with non-small cell lung cancer. J Xinjiang Med Univ 2009;2:165-8.
12. Nisman B, Lafair J, Heching N, Lyass O, Baras M, Peretz T, et al. Evaluation of tissue polypeptide specific antigen, CYFRA 21-1, and carcinoembryonic antigen in nonsmall cell lung carcinoma: Does the combined use of cytokeratin markers give any additional information? Cancer 1998;82:1850-9.
13. Pujol JL, Boher JM, Grenier J, Quantin X. Cyfra 21-1, neuron specific enolase and prognosis of non-small cell lung cancer: Prospective study in 621 patients. Lung Cancer 2001;31:221-31.
14. Molina R, Augé JM, Bosch X, Escudero JM, Violas N, Marrades R, et al. Usefulness of serum tumor markers, including progastrin-releasing peptide, in patients with lung cancer: Correlation with histology. Tumour Biol 2009;30:121-9.
15. Pavicevic R, Bubanovic G, Franjevic A, Stancic-Rokotov D, Samarzija M. CYFRA 21-1 in non-small cell lung cancer - standardisation and application during diagnosis. Coll Antropol 2008;32:485-98.
16. Lai RS, Hsu HK, Lu JY, Ger LP, Lai NS. CYFRA 21-1 enzyme-linked immunosorbent assay. Evaluation as a tumor marker in non-small cell lung cancer. Chest 1996;109:995-1000.
17. Muraki M, Tohda Y, Iwanaga T, Uejima H, Nagasaka Y, Nakajima S. Assessment of serum CYFRA 21-1 in lung cancer. Cancer 1996;77:1274-7.
18. Kim YC, Park KO, Choi IS, Kim HJ, Lim SC, Bom HS. A comparison of serum CYFRA 21-1 and SCC Ag in the diagnosis of squamous cell lung carcinoma. Korean J Intern Med 1996;11:50-7.
19. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63:11?30.
20. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10?29.
21. Stieber P, Hasholzner U, Bodenmller H, Nagel D, Sunder?Plassmann L, Dienemann H, et al. CYFRA 21?1. A new marker in lung cancer. Cancer 1993;72:707?13.
22. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982;143:29-36.